Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

In 2026, biotechnology is experiencing a pivotal shift as landmark clinical results, regulatory reforms, and in vivo therapeutic platforms move from concept to practice. Breakthroughs such as the ...

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S.

Odyssey Therapeutics secured a valuation of $899.9 million after its ​shares rose 11.1% in their Nasdaq debut on Friday, ...

Sara Ahmed ’26, a student in the MBA for Executives program, drew on her background in biotech to craft a speaker series ...

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.

In 2026, biotechnology shifted from promise to proof as the first fully AI-designed drug showed positive human trial results, CRISPR therapies expanded into new disease areas, and the FDA enforced ...

May 7 (Reuters) - Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public ...

Andrew Hillman Grant for Biotech Introduces National Opportunity for Undergraduate Talent to Explore the Future of ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...